Ageas: Highlights ING Benelux Conference London. Alfen: Highlights from ING Benelux Conference London. Arcadis: Highlights ING Benelux Conference London. ASR: Highlights ING Benelux Conference London. BAM: Highlights ING Benelux Conference London. Basic-Fit: Highlights ING Benelux Conference London. CTP: Highlights from ING Benelux Conference London. DEME Group: Highlights ING Benelux Conference London. Fugro: Highlights ING Benelux Conference London. Heijmans: Highlights ING Bene...
Vopak Terquimsa divested terminal in Barcelona Vopak Terquimsa divested terminal in BarcelonaRotterdam, the Netherlands, 8 September 2025Vopak Terquimsa, (a joint venture in which Vopak has a 50% share) has divested its Barcelona terminal to Tradebe Port Services. The Barcelona terminal is mainly used for the storage of petroleum products, chemicals and vegetable oils.The Barcelona terminal is for Vopak less strategically attractive, Vopak remains a 50% shareholder in Vopak Terquimsa Tarragona, this terminal is located within the industrial cluster of Tarragona, Spain.Vopak will report an e...
In this September update we added 2 stocks to the KBC Securities Dynamic Top Pick List : We added AB InBev after the share price weakened post-2Q results. ABI's 2Q volumes fell 1.9% organically, below expectations, mainly due to a 9% drop in Brazil where a price hike led to temporary market share loss. However, strong revenue per hl growth (+4.9%) drove a 6.5% organic EBITDA increase, with 1H growth at +7.2%, near the top of FY guidance (+4–8%). AB InBev, the world's largest brewer, generates ...
Zealand Pharma to participate in upcoming investor conferences in September 2025 Press release – No. 12 / 2025 Zealand Pharma to participate in upcoming investor conferences in September 2025 Copenhagen, Denmark, August 28, 2025 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that the company will participate in the following investor conferences in September 2025. Jefferies Swiss Healthcare Summit 2025, September 3 in Zürich Adam Lange, Vice President, Investo...
Zealand Pharma major shareholder announcement: Van Herk Investments B.V. Company announcement – No. 19 / 2025 Zealand Pharma major shareholder announcement: Van Herk Investments B.V. Copenhagen, Denmark, August 20, 2025 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today reports receipt on 20 August 2025 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholder: As of 19 August 2025, Van Herk Investments B.V. (Du...
Zealand's 2Q25 results hold no surprises, and show that the company is on track operationally with pipeline timelines being reiterated. While no big data readouts are expected for the remainder of the year, the company is gearing up for a news heavy 1H26 and we most look forward to phase 2b results with petrelintide (amylin analog, partnered with Roche). Zealand reported a cash position of DKK 16,578m, and expects an additional $ 250m in anniversary payments under the Roche agreement in addition...
Zealand Pharma Announces Financial Results for the First Half of 2025 Company announcement – No. 18 / 2025 Zealand Pharma Announces Financial Results for the First Half of 2025Petrelintide collaboration with Roche off to a strong start, while key leadership appointments and solid financial position enable exciting next chapter for Zealand Pharma. Collaboration and license agreement with Roche to co-develop and co-commercialize petrelintide as a future foundational therapy for weight management off to a strong start, with further insight and updates expected at Roche’s Pharma Day in Septe...
bpost: 2Q25 results beat 22%, outlook raised further, room for another upgrade at 3Q25. Lotus Bakeries: APAC factory ahead of schedule. NN Group: 1H on track with May CMD, longevity deal a positive surprise (Sol 2 PF 205%). Talabat: 2Q25 Preview. Vopak: AVTL's FID on Mumbai expansion
42% owned AVTL announced a €170m investment in a greenfield LPG terminal and bottling plant. LPG demand in India has grown at a 7.3% CAGR over the past decade with further attractive growth in demand and terminal imports expected. The Indian JV AVTL was recently listed and the IPO proceeds amounted to ca. €290m to be deployed for debt repayment and further growth initiatives. The listing frees up cash at the Vopak holding which can be deployed for funding other investments or additional sharehol...
AVTL to develop new terminal in JNPA, India AVTL to develop new terminal in JNPA, IndiaRotterdam, the Netherlands, 8 August 2025In India, AVTL announced a positive final investment decision to build a greenfield terminal for 132k cbm LPG and 318k cbm liquid products and a LPG bottling plant of 35,000MT capacity in the JNPA port in Mumbai. This is AVTL's second terminal in the JNPA port which will help grow its market share in servicing a highly industrialized and fast growing hinterland of West and central regions in India. The terminal is expected to be commissioned in phases starting mid ...
Zealand Pharma conference call on August 14 at 2pm CET (8am ET) to present second quarter 2025 financial results Press Release – No. 11 / 2025 Zealand Pharma conference call on August 14 at 2pm CET (8am ET) to present second quarter 2025 financial results Copenhagen, Denmark, August 7, 2025 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on August 14, 2025, at 2:00 pm CET (8:00 am ET) following the announcement of financia...
Vopak reported 2Q25 which were better than expected with proportional EBITDA of €315m vs consensus of €291m. Overall the company has been coping well with all current macro uncertainties. The full year EBITDA outlook bandwidth was even narrowed to the upside and this when taking into account less favourable FX rates. The IPO of the Indian JV resulted in an €111m capital gain impacting IFRS net profit. Occupancy rates are holding up well at 91%, flat vs. last quarter. We reiterate Buy and € 50 TP...
Aedifica: Strong results, guidance reiterated; dsm-firmenich: Symrise 1H25 results; IMCD: Stagnating gross profit leads to disappointing 2Q25 EBITA; JDE Peet's: Full of beans; Just Eat Takeaway: 1H25 results, weak update no impact on takeover; Lotus Bakeries: Peer Mondelez 1Q25 results; Melexis: 2Q25 results, gross margin under pressure; Solvay: 2Q25 in line, subdued outlook no surprise after pre-release; TKH Group: Preview: Under a magnifying glass; Universal Music Group: Spotify 2Q25 ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.